Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Inhibikase Therapeutics, Inc.

NASDAQ: IKT · Life Sciences · 3 alerts · CIK 1750149

Share price
$1.45Close, Nov 16
Market cap
$203M
Shares outstanding
140.27MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Inhibikase Therapeutics, Inc. filings on SEC EDGAR ↗

4:58 PM ET 8-K
Leadership Change

Inhibikase Therapeutics Leadership Change

Inhibikase Therapeutics appointed Dr. Scott Wasserman to its Board of Directors and the Compensation Committee, effective October 19, 2026. Dr. Wasserman, currently CMO of Kailera Therapeutics and a former Amgen executive, succeeds Dennis Berman, who resigned from the Board on the same date. The change occurs as the company advances its Phase 3 IMPROVE-PAH study of IKT-001.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.